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Abstract
Background—RNA sequences of the re-
cently identified hepatitis GB virus C
(HGBV-C), also named hepatitis G virus
(HGV), have been detected in patients
with idiopathic fulminant hepatic failure
(FHF) but the role of this agent in the dis-
ease remains controversial.
Aims—To investigate the presence and
implications of HGV infection in a large
series of Spanish patients with FHF.
Patients—Sixty eight patients with FHF,
including 19 with idiopathic disease, were
studied. In 28 cases, studies were per-
formed before and after liver transplanta-
tion. For comparison 200 volunteer blood
donors and 22 patients transplanted for
chronic liver disease were also studied.
Methods—HGV RNA was measured in
serum by reverse transcriptase polymerase
chain reaction of the 5' non-coding region.
Results—Evidence of HGV infection was
found in 3% (6/200) of blood donors and in
19% (13/68) of patients with FHF. HGV
infection was more frequent in patients
with hepatitis B (24%, 6/25) or hepatitis D
(42%, 5/12), than in patients with idio-
pathic disease (11%, 2/19). Half of the
patients with HGV infection used illicit
intravenous drugs. Specific clinical fea-
tures associated with HGV infection were
not identified. A very high rate of infection
with HGV was observed in patients who
underwent liver transplantation, either for
FHF (60%, 15/24) or chronic liver disease
(45%, 9/20).
Conclusions—In our geographical area,
HGV infection is relatively frequent in
FHF, but it does not seem to play a major
role in idiopathic cases.
(Gut 1997; 41: 696–699)
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Fulminant hepatic failure (FHF) is a dramatic
condition resulting from severe impairment of
the function of a previously normal liver.1 Mas-
sive or submassive destruction of hepatocytes
as a consequence of infection with hepatitis
viruses A to E is the most frequently recognised
cause of FHF worldwide, but the aetiology
cannot be identified in approximately one third
of patients.2 The nature of the agent or agents
causing idiopathic fulminant hepatic failure
remains elusive and several studies have yielded
conflicting results.3–7
Recently, a new transmissible agent, the
hepatitis GB virus C (HGBV-C) has been
identified.8 This virus belongs to the Flaviviri-
dae family and presents notable sequence simi-
larity with another agent, the hepatitis G virus
(HGV), identified in an independent
laboratory.9 HGBV-C and HGV are diVerent
isolates of the same virus.10
The role of this agent in human liver disease
is currently under investigation. Preliminary
data indicate that HGV/HGBV-C infection can
be detected in a relatively high proportion of
apparently healthy volunteer blood donors, in
persons exposed to parenterally transmitted
viruses such as recipients of blood transfusions,
patients on haemodialysis, intravenous drug
abusers, and institutionalised patients, and in
patients with acute and chronic liver
disease.8 9 11–18 However, the information con-
cerning the prevalence and the pathogenic role
of HGV infection in these situations is still
rather limited.19
The presence of HGBV-C RNA sequences
has recently been demonstrated in serum from
50% of patients with idiopathic fulminant
hepatitis,20 21 suggesting that this virus may
have a role in the aetiology of this disease.
These findings, however, were not fully con-
firmed by others.18 22–31
Several surveys on the aetiology of FHF
demonstrated remarkable diVerences between
diVerent geographical areas.32–36 We therefore
investigated the possible role of HGV infection
in a relatively large series of Spanish patients
with FHF of known aetiology and in a
representative group of patients with idiopathic
disease.
Patients and Methods
PATIENTS
Between January 1987 and December 1995,
108 patients with fulminant hepatic failure
(FHF), according to the criteria of Trey and
Davidson,1 were admitted to the Liver Intensive
Care Unit of the Hospital Clínic, Barcelona.
Sixty four patients (60%) were admitted directly
and 44 patients (40%) were transferred from
other centres in Spain for specialised care. Well
preserved serum samples taken at admission
were available in 68 cases (65%) and these
patients formed the basis of the present study.
Recent exposure to hepatotoxic drugs and risk
factors for transmission of hepatotropic viruses,
including recent administration of blood or
blood products, were recorded in every case.
The aetiology of the disease was defined by
standard clinical, serological, biochemical, and
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histopathological studies.2 The clinical presenta-
tion of the disease as hyperacute, acute, or suba-
cute was defined by the criteria of O’Grady et
al.37 Patients received standard supportive
therapy2 and an orthotopic liver transplantation
was performed in 28 cases, according to criteria
reported previously.38 Twenty two randomly
selected patients with chronic liver disease who
received a liver transplant during the same
period of time and 200 consecutive, first
donation, volunteer blood donors were also
studied for comparative purposes.
SEROLOGICAL STUDIES
The presence of current infection with hepatitis
A virus (HAV), hepatitis B virus (HBV), hepati-
tis D virus (HDV), or hepatitis C virus (HCV)
was assessed with commercially available en-
zyme linked immunosorbent assay (ELISA) kits
(HAVAB-M EIA, Auszyme II, Corzyme M,
Anti-delta EIA, Abbott Laboratories, Chicago,
Illinois, USA), for antihepatitis A IgM, hepatitis
B surface antigen, antihepatitis B core IgM anti-
bodies, and total antihepatitis D, respectively,
and for antihepatitis C virus antibodies (second
and third generation Anti-HCV ELISA test,
Ortho Diagnostics Systems, Raritan, New Jer-
sey,USA).HCVRNAwas investigated in serum
with a nested polymerase chain reaction (PCR)
assay, using primers derived from the 5'
non-coding region (5' NCR) of the HCV
genome, as described previously.39
Hepatitis G virus RNA (HGV RNA) in
serum was determined by a commercially avail-
able assay kit (Boehringer Mannheim, Mann-
heim, Germany) for PCR amplification of the
5' NCR of the HGV genome as described
previously.15 Briefly, nucleic acids were ex-
tracted from 140 µl of serum using QUIAMP-
HCV extraction columns (Qiagen, Hilden,
Germany). Eluted RNA was transcribed into
cDNA with Moloney murine leukaemia virus
retrotranscriptase in the presence of random
primers and a ribonuclease inhibitor. PCR was
carried out for 35 cycles (94ºC, one minute;
55ºC, one minute; 72ºC, one minute) and five
minutes at 72ºC for final extension using 10 µl
of a cDNA, dNTP mixture containing 200 µM
of dATP, dGTP, and dCTP, 190 µM of dUTP,
10 µM of digoxigenin-11-dUTP, 50 pmol of
primers NCR1 (5'-CGGCCAAAAGGTGG-
TGGATG-3') and NCR2 (5'-CGACGAGCC-
TGACGTCGGG-3'), that encompass a 184 bp
fragment of the 5' NCR, and 1.25 U of Taq
DNA polymerase in a final volume of 50 µl.
Digoxigenin labelled PCR products were de-
tected by hybridisation for one hour at 37ºC
(DIG-ELISA detection kit, Boehringer Mann-
heim, Mannheim, Germany) with a capture
probe (5'-biotin-CGTAGCCACTATAGGTG-
GG-3') immobilised on streptavidin coated
microtitre plates. After hybridisation, wells were
incubated with digoxigenin peroxidase and
washed. Absorbance was read at 405 nm (refer-
ence filter at 492 nm). Two negative and one
positive control sera were included in PCR
reactions and three blanks were included in
each hybridisation reaction. All samples were
tested at least twice in separate rounds. Samples
were considered positive when the measured
absorbance was greater than four times the
mean absorbance obtained in negative controls,
in which the signal ranged between 0.084 and
0.113. Results were accepted on agreement
between at least two separate determinations.
The NS3 region of the HGBV-C genome
was analysed in all the samples reactive for 5'
NCR sequences of HGV RNA and in 15 non-
reactive samples selected at random from
patients with FHF. RT-PCR was performed as
described by Yoshiba et al20 with some
modifications,12 using primers deduced from
the nucleotide sequence of HGBV-C described
by Simons et al.8
STATISTICAL ANALYSIS
DiVerences in proportions between groups
were analysed with the ÷2 test and Fisher’s
exact test. Quantitative variables were analysed
with Student’s t test or the Mann-Whitney test
when appropriate.
Results
Table 1 shows the main features of the patients
with FHF. Anti-HAV antibodies of the IgM
class were detected in three cases, HBsAg and
anti-HBc of the IgM class in 25, HBsAg and
anti-HDV antibodies in 12, and anti-HCV and
HCV RNA in two. These findings suggested
that infection with hepatotropic viruses was the
cause of FHF in 42 cases (62%). A recent his-
tory of potentially hepatotoxic drug intake was
recorded in five patients (antituberculous drug
therapy in three, ketoconazole in one, and
halothane in one). Massive involvement of the
liver by previously unrecognised lymphoma
was found in one case and evidence of Wilson’s
disease was detected in another. A possible
aetiological factor was not found in the
remaining 19 cases (28%).
A positive signal for the 5' NCR of the HGV
genome was detected in serum from 13/68
patients with FHF (19%) and in 6/200 blood
donors (3%) tested (Fisher’s exact test,
p<0.001). Sequences of the NS3 region of the
HGBV-C genome were detected in the 13
serum samples positive for the 5' NCR of HGV
but in none of 15 samples negative for HGV
RNA.
TABLE 1 Main features of patients with fulminant hepatic failure according to the presence
or absence of HGV RNA sequences in serum
HGV RNA
Total (n=68) Present (n=13) Absent (n=55)
Age (y) 30 (13) 29 (11) 30 (14)
Sex (M/F) 32/36 8/5 24/31
Presumed source of infection
Intravenous drug abuse 18 6 (33%) 12 (66%)
Sexual 11 3 (27%) 8 (73%)
Unknown 39 4 (10%) 35 (90%)
Presumed aetiology
HAV 3 0 3 (100%)
HBV 25 6 (24%) 19 (76%)
HBV/HDV 12 5 (42%) 7 (58%)
HCV 2 0 2 (100%)
Miscellaneous non-viral 7 0 7 (100%)
Idiopathic 19 2 (11%) 17 (89%)
Clinical presentation
Hyperacute 26 4 (15%) 22 (85%)
Acute 30 4 (13%) 26 (87%)
Subacute 12 5 (42%) 7 (58%)
Final outcome
Recovery 9 4 (44%) 5 (56%)
Death 21 5 (24%) 16 (76%)
Liver transplantation 38 4 (11%) 34 (89%)
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The presence of HGV RNA in serum from
patients with FHF did not seem to be related to
previous administration of frozen plasma as
supportive therapy for coagulation disorders.
This therapy was administered within two days
prior to collection of serum for HGV RNA
testing in 17 cases. HGV RNA was found in
3/17 treated patients (21%) and in 10/41
(24%) who did not receive supportive therapy.
HGV RNA was detected with greater
frequency in patients with a history of
intravenous use of illicit drugs (6/18, 33%)
than in patients with no risk factors (4/39,
10%) (Fisher’s exact test, p=0.04) (table 1).
The presence of HGV RNA sequences in
serum was more frequent in patients with HBV
infection, with (5/12, 42%) or without (6/25,
32%) evidence of HDV infection, than in
patients with idiopathic disease (2/19, 11%).
However, this diVerence did not reach statisti-
cal significance (Fisher’s exact test, p=0.058).
HGV RNA was not detected in patients with
HAV or HCV infection nor in those with mis-
cellaneous conditions other than viral infection
(table 1).
Neither the clinical presentation of the
diseases as hyperacute, acute, or subacute, nor
the final outcome of the disease seemed to be
related to the presence in serum of HGV RNA
sequences (table 1). The proportion of patients
presenting with HGV RNA among those who
recovered with conventional measures (4/9,
44%) was somewhat greater than among
patients who died (5/21, 24%) or underwent
liver transplantation (4/38, 9%). None of these
diVerences reached statistical significance.
Liver transplantation was performed in 38
patients with FHF. Six of them died shortly
after the operation and four were not followed
at our institution. Serum samples obtained six
months after transplantation were available for
the remaining 28 patients. HGV RNA was
detected in pretransplant samples in four of
these patients.
Twenty two randomly selected patients trans-
planted for chronic liver disease (16 males, six
females; mean age 50 years, range 36–59) were
also studied. The indication for transplantation
was hepatic cirrhosis in 21 cases (related to
hepatitis C virus infection in 13, of alcoholic
type in five, primary biliary cirrhosis in one, and
cryptogenic in two), and advanced primary scle-
rosing cholangitis in one. HGV RNA was
detected in pretransplant serum samples in two
of these patients. After transplantation, HGV
RNA was detected in 19 (68%) patients with
FHF and in 11 (50%) with chronic liver disease.
No patient clearedHGVRNA after transplanta-
tion.HGVRNA thus emerged after transplanta-
tion in 15/24 (60%) patients transplanted for
FHF and in 9/20 (45%) of those transplanted
for chronic liver disease.
The number of donors of blood, platelets, or
other blood components involved in the trans-
plantation procedure was greater in patients
transplanted for FHF (61 (50)) than in patients
transplanted for chronic liver disease (36 (24)),
but the diVerence was not statistically signifi-
cant.
Discussion
Despite intensive investigation, the cause of the
disease remains obscure in a considerable
proportion of patients with FHF. Hidden viral
infection, not identifiable with ordinary sero-
logical techniques, may be responsible in some
cases of idiopathic FHF.3 4 Infection with a
previously unrecognised virus, such as HCV in
the East33 34 or HEV in developing countries37
may be involved in others.However, despite the
use of complex molecular biology techniques
to identify viral nucleic acid in liver or serum,
the aetiology of FHF cannot be reliably identi-
fied in many patients. Idiopathic FHF is there-
fore often referred as non-A, non-E fulminant
hepatitis.
The HGBV-C or HGV is a recently
identified transmissible agent that can cause
hepatitis in man.8 9 HGBV-C genome se-
quences have been detected in serum from
patients with non-A, non-E fulminant hepati-
tis, and this finding suggested that HGBV-C
might be involved in the pathogenesis of this
disease.20 21 However, other groups did not
share this opinion.22 31
In the current study HGV RNA sequences
were detected in 19% of Spanish patients with
FHF. The specificity of this finding is sup-
ported by the highly concordant results ob-
tained by reverse transcriptase PCR amplifica-
tion of viral RNA using primers derived from
the 5' NCR of HGV and the NS3 region of
HGBV-C.
In comparison with other studies,20 21 the large
number of HGV RNA negative cases of FHF
found in this study may be related to inadequate
preservation of RNA in serum samples or to low
sensitivity of the reverse transcriptase PCR
assay. This is, however, unlikely because the fre-
quency of HGV infection observed in our
patients with chronic liver disease, and in blood
donors, was in the range observed in previous
studies8 9 11–18 or even higher. In addition, low
prevalence of HGV infection has also been
reported by others.30
Patients with fulminant viral hepatitis charac-
teristically have low levels of viraemia, which
may escape detection35 40 unless very sensitive
techniques are used for detection. Theoretically,
hidden viral infection might become apparent if
patients are transplanted and treated with
immunosuppressive drugs, as has been reported
in patients transplanted for chronic liver
disease.41 In the present study, HGV infection
became apparent after transplantation in as
many as 60% of the patients with FHF. Hidden
HGV infection might thus be present in many
more patients than indicated by pretransplant
studies. This is not likely, however, as HGV
infection became apparent in a similar
proportion of patients transplanted for chronic
liver disease. The high rate of post-transplant
HGV infection observed in this study can be
explained by the large number of blood donors
involved in the transplantation procedure, in
whom the estimated prevalence of HGV infec-
tion was as high as 3%.
On the other hand, it is possible that
detection of HGV RNA by reverse tran-
scriptase PCR in patients with FHFmay not be
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due to a current infection with this agent but
simply reflect passive transmission of HGV
material present in fresh frozen plasma or other
blood products administered as treatment for
clotting disorders. In this study, however, HGV
RNA sequences were detected with a similar
frequency in treated and untreated patients.
Eleven of the 13 patients with FHF in whom
HGV RNA was detected in serum also
presented evidence of infection with HBV or
with HBV and HDV. The majority of these
patients were intravenous drug abusers or had
a recent history of sexual contact with drug
addicts (data not shown). HGV RNA was
detected in approximately one third of FHF
patients with HBV, in agreement with recent
observations indicating that the majority of
patients with FHF infected with HGV are also
infected with HBV.18 21 31 In contrast, HGV
RNA was detected at a lower frequency in
patients with idiopathic disease and was not
found at all in patients with hepatitis A or
hepatitis C, or in those with miscellaneous
conditions.
It has recently been recognised that multiple
viral infection, involving well known, readily
identifiable viruses such as HBV, HDV, and
HCV, can be detected in many patients with
fulminant hepatitis.35 Our data suggest that a
role for HGV infection as a cofactor in patients
with fulminant hepatitis infected with HBV or
HDV cannot be disregarded. Infection with
HGV alone, however, does not seem to be a
major cause of idiopathic fulminant hepatitis in
our geographical area.
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